UCP2 - Taking the heat out of P-glycoprotein?

Richard Callaghan , Mary Board
Cancer Drug Resistance 3

2021
The utilisation of glutamine and glucose by a 3-D tumour model trapped in quiescence.

Jacqueline Boultwood , Richard Callaghan , Richard Callaghan , Malcolm McConville
The International Journal of Biochemistry & Cell Biology 133 105935 -105935

2021
Exploiting the metabolic energy demands of drug efflux pumps provides a strategy to overcome multidrug resistance in cancer.

Richard Callaghan , Mary Board , Xuexin Gao , Doriane Aguanno
Biochimica et Biophysica Acta 1865 ( 8) 129915 -129915

2021
Purification and structural analyses of ABCG2

Christopher A. McDevitt , Richard Collins , Ian D. Kerr , Richard Callaghan
Advanced Drug Delivery Reviews 61 ( 1) 57 -65

23
2009
Modulation of the BK channel by estrogens: examination at single channel level.

Heidi De Wet , Marcus Allen , Chris Holmes , Michelle Stobbart
Molecular Membrane Biology 23 ( 5) 420 -429

30
2006
Structure of the Multidrug Resistance P-glycoprotein to 2.5 nm Resolution Determined by Electron Microscopy and Image Analysis

Mark F. Rosenberg , Richard Callaghan , Robert C. Ford , Christopher F. Higgins
Journal of Biological Chemistry 272 ( 16) 10685 -10694

303
1997
Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2

Christopher A. McDevitt , Emily Crowley , Gemma Hobbs , Kate J. Starr
FEBS Journal 275 ( 17) 4354 -4362

38
2008
The central cavity of ABCB1 undergoes alternating access during ATP hydrolysis.

Jessica H. van Wonderen , Róisin M. McMahon , Megan L. O'Mara , Christopher A. McDevitt
FEBS Journal 281 ( 9) 2190 -2201

32
2014
Cross-linking, DEER-spectroscopy and molecular dynamics confirm the inward facing state of P-glycoprotein in a lipid membrane

Alex R. Carey Hulyer , Deborah A. Briggs , Megan L. O'Mara , Ian D. Kerr
Journal of Structural Biology 211 ( 1) 107513

2
2020
Synthesis and Pharmacological Evaluation of Noscapine-Inspired 5-Substituted Tetrahydroisoquinolines as Cytotoxic Agents

Shane M. Devine , Cassandra Yong , Dzifa Amenuvegbe , Luigi Aurelio
Journal of Medicinal Chemistry 61 ( 18) 8444 -8456

8
2018
The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein.

Catherine Martin , Christopher F. Higgins , Richard Callaghan
Biochemistry 40 ( 51) 15733 -15742

88
2001
The coupling mechanism of P-glycoprotein involves residue L339 in the sixth membrane spanning segment

Alice Rothnie , Janet Storm , Roisin McMahon , Andrew Taylor
FEBS Letters 579 ( 18) 3984 -3990

31
2005
The translocation mechanism of P-glycoprotein

Richard Callaghan , Robert C. Ford , Ian D. Kerr
FEBS Letters 580 ( 4) 1056 -1063

137
2006
Structure of the multidrug resistance P-glycoprotein

Christopher F. Higgins , Richard Callaghan , Kenneth J. Linton , Mark F. Rosenberg
Seminars in Cancer Biology 8 ( 3) 135 -142

93
1997
Basis for design and development of platinum(IV) anticancer complexes.

Matthew D. Hall , Howard R. Mellor , Richard Callaghan , Trevor W. Hambley
Journal of Medicinal Chemistry 50 ( 15) 3403 -3411

473
2007
Survivin isoform Delta Ex3 regulates tumor spheroid formation

Magali Espinosa , Gisela Ceballos-Cancino , Richard Callaghan , Vilma Maldonado
Cancer Letters 318 ( 1) 61 -67

10
2012
Location of contact residues in pharmacologically distinct drug binding sites on P-glycoprotein.

Rituparna Mittra , Megan Pavy , Nanditha Subramanian , Anthony M. George
Biochemical Pharmacology 123 19 -28

17
2017
Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane

Richard Callaghan , John R Riordan
Biochimica et Biophysica Acta 1236 ( 1) 155 -162

26
1995
Providing a molecular mechanism for P-glycoprotein; Why would i bother?

Richard Callaghan
Biochemical Society Transactions 43 ( 5) 995 -1002

25
2015
Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?

Edward Norris-Cervetto , Terry D. Butters , Catherine Martin , Szabolcs Modok
European Journal of Pharmacology 530 ( 3) 195 -204

3
2006